GLP-1 receptor is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-01-21. Where a claim depends on a specific study, the study is described rather than over-claimed.
Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.
The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.
Structure-activity work shows that fatty acid length, linker chemistry and the position of acylation all influence albumin affinity and receptor potency. Plasma protein binding exceeds 99 percent, which restricts distribution and slows renal clearance. Degradation proceeds largely through general proteolysis and fatty acid oxidation rather than cytochrome P450 metabolism, so exposure to common oxidative drug interactions is limited. Whether these clearance routes vary meaningfully between individuals is not fully established.
The molecule is a synthetic 39-amino-acid peptide whose backbone derives from the sequence of human glucose-dependent insulinotropic polypeptide, with several substitutions that raise metabolic stability and shift receptor preference. A C20 fatty diacid is attached through a short linker to a lysine side chain, a modification that increases binding to serum albumin. The reported monoisotopic mass is approximately 4813 Da. Near neutral pH the peptide carries a net negative charge, and the lipid tail makes the molecule markedly more hydrophobic than the unmodified parent sequence.
Dual agonism at the GIP and GLP-1 receptors underlies the observed pharmacology. Activation of GLP-1 receptors raises glucose-dependent insulin release, lowers glucagon secretion, slows gastric emptying and reduces appetite. GIP receptor activation contributes additional effects on adipose tissue and on energy balance, and the combined action on appetite appears larger than either pathway alone in animal models. Signalling bias and the relative contribution of each receptor arm to weight-related effects remain areas of active investigation.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Modified synthetic peptide | 39-residue backbone with non-natural residues |
| Receptor targets | GIP and GLP-1 | Dual incretin receptor agonist |
| Approximate molecular mass | 4,813 Da | Calculated from the peptide sequence |
| Administration route | Subcutaneous injection | Weekly schedule in approved products |
| Albumin binding | Present | Mediated by a C20 fatty diacid side chain |
Identity and purity are usually established with reversed-phase high-performance liquid chromatography for the main peak and with mass spectrometry for the observed molecular mass. Peptide mapping after enzymatic digestion confirms the primary sequence, while amino acid analysis provides a quantitative composition check. Size-exclusion chromatography and ion-exchange chromatography are used to look for aggregates and charge variants. Water content, residual solvents, and counter-ion content are measured separately, since a lyophilised powder is often reported on an as-is basis unless a correction is applied.
Research-grade material circulates through suppliers that differ widely in documentation and testing practice, so a certificate of analysis is a starting point rather than proof of quality. Independent verification typically repeats chromatographic purity and mass confirmation on the received lot, and compares results against a retained reference standard. Regulatory status varies by jurisdiction, and a substance cleared as a medicine is not interchangeable with a research chemical of the same name. Open questions include how closely non-pharmaceutical lots match approved material in impurity profile and in aggregate content.
In clinical research, tirzepatide has been studied in randomized controlled trials for glycemic control and body weight reduction. These trials typically measure changes in hemoglobin A1c and body weight over periods of several months. The drug is administered by subcutaneous injection, and its pharmacokinetic profile supports once-weekly dosing. Post-marketing surveillance continues to evaluate long-term outcomes and rare adverse events.
Tirzepatide is a synthetic peptide that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The molecule contains 39 amino acids and features a C20 fatty diacid moiety attached via a linker, which promotes albumin binding and extends its circulating half-life. Its sequence incorporates non-natural amino acids and modifications that reduce susceptibility to degradation by dipeptidyl peptidase-4. This dual receptor activity distinguishes it from selective GLP-1 receptor agonists.
β-Lactams may form an adduct E-I* of high stability with DD-transpeptidase. The half life of this adduct is around hours, whereas the half-life of the normal reaction is in the order of milliseconds. The interference with the enzyme processes responsible for cell wall formation results in cellular lysis and death due to the triggering of the autolytic system in the bacteria.
In contrast to early inefficient dry- packing methods, wet slurry packing, in which particles that are suspended in an appropriate solvent are delivered into a column under pressure, shows significant improvement. Three different approaches can be employed in performing wet slurry packing: the balanced density method (solvent's density is about that of porous silica particles), the high viscosity method (a solvent of high viscosity is used), and the low viscosity slurry method (performed with low viscosity solvents). Polystyrene is used as a medium for ion-exchange. It is made from the polymerization of styrene with the use of divinylbenzene and benzoyl peroxide. Such exchangers form hydrophobic interactions with proteins which can be irreversible. Due to this property, polystyrene ion exchangers are not suitable for protein separation. They are used on the other hand for the separation of small molecules in amino acid separation and removal of salt from water. Polystyrene ion exchangers with large pores can be used for the separation of protein but must be coated with a hydrophilic substance. Cellulose based medium can be used for the separation of large molecules because they contain large pores. Protein binding in this medium is high and has low hydrophobic character. DEAE is an anion exchange matrix that is produced from a positive side group of diethylaminoethyl bound to cellulose or Sephadex. Agarose gel based medium contain large pores as well but their substitution ability is lower in comparison to dextrans.
==== Finished brand ==== One of the reasons freeze branding produces such a crisp mark in healed animals is that at the edge of the zone of melanocyte death, there remains a border of melanocytes that have merely been stressed. These stressed melanocytes thereafter express more melanin. This provides a subtle outline to the pattern of white hair, increasing the definition of its edge and legibility, if alphanumeric. At three months the process is generally complete for livestock and the full freeze brand is visible.
The purest metal is obtained from nickel oxide by the Mond process, which gives a purity of over 99.99%. The process was patented by Ludwig Mond and has been in industrial use since before the beginning of the 20th century. In this process, nickel is treated with carbon monoxide in the presence of a sulfur catalyst at around 40–80 °C to form nickel carbonyl. In a similar reaction with iron, iron pentacarbonyl can form, though this reaction is slow. If necessary, the nickel may be separated by distillation. Dicobalt octacarbonyl is also formed in nickel distillation as a by-product, but it decomposes to tetracobalt dodecacarbonyl at the reaction temperature to give a non-volatile solid. Nickel is obtained from nickel carbonyl by one of two processes. It may be passed through a large chamber at high temperatures in which tens of thousands of nickel spheres (pellets) are constantly stirred. The carbonyl decomposes and deposits pure nickel onto the spheres. In the alternate process, nickel carbonyl is decomposed in a smaller chamber at 230 °C to create a fine nickel powder. The byproduct carbon monoxide is recirculated and reused. The highly pure nickel product is known as "carbonyl nickel".
=== 1975 === 12 April: Juanita Mott (18). Mott had been a former lodger at 25 Cromwell Street but was living with a family friend in Newent when she disappeared. Mott is believed to have been abducted by the Wests as she hitchhiked along the B4215. In his subsequent confessions to police, Fred would refer to Mott as "the girl from Newent".
Sources: en.wikipedia.org
=== Restoration === The role of ectomycorrhizas in supporting their host plants has led to the suggestion that EcM fungi could be used in restoration projects aimed at re-establishing native plant species in ecosystems disrupted by a variety of issues. Since the disappearance of mycorhizal fungi from a habitat constitutes a major soil disturbance event, their re-addition is an important part of establishing vegetation and restoring habitats.
=== Epilepsy === Lorcaserin is under development for the treatment of Dravet syndrome, Lennox–Gastaut syndrome, and other forms of epilepsy. As of 2024 and 2025, it is in phase 3 clinical trials for Dravet syndrome and the preclinical research stage of development for Lennox–Gastaut syndrome. It is being developed by Eisai and Epygenix, including under the developmental code name EPX-200. Though lorcaserin is or was under development by Eisai for Dravet syndrome, this development is said to have been discontinued in late 2024.
Once active, Akt translocates from the plasma membrane to the cytosol and nucleus, where many of its substrates reside. Akt regulates a wide range of proteins by phosphorylation. Akt target substrates contain a minimum consensus sequence R-X-R-X-X-[Ser/Thr]-Hyd, where Hyd is a hydrophobic amino acid, although other factors such as sub-cellular localisation and 3-dimensional structure are important. Phosphorylation by Akt can be inhibitory or stimulatory, either suppressing or enhancing the activity of target proteins.
=== Nutrition === Calcium is a common constituent of multivitamin dietary supplements, but the composition of calcium complexes in supplements may affect its bioavailability which varies by solubility of the salt involved: calcium citrate, malate, and lactate are highly bioavailable, while the oxalate is less. Other calcium preparations include calcium carbonate, calcium citrate malate, and calcium gluconate. The intestine absorbs about one-third of uncomplexed calcium consumed, and plasma calcium level is then regulated by the kidneys.
Sources: en.wikipedia.org
It binds and activates both the GIP and GLP-1 receptors, making it a dual incretin receptor agonist. Single-receptor GLP-1 agonists act on one target only. The dual profile is the defining pharmacological feature of the molecule.
A fatty diacid side chain promotes reversible binding to serum albumin. This association slows renal clearance and protects the peptide from rapid enzymatic degradation. The result is a prolonged circulation time that supports weekly administration.
The first regulatory approval, for type 2 diabetes, was granted in the United States in 2022. An additional approval for chronic weight management followed in 2023. Availability and approved indications vary by country and are set by each national regulator.
It is a synthetic peptide of 39 amino acids bearing a lipid side chain. Its size and architecture place it outside the small-molecule class, and laboratories generally handle it with the precautions used for biologic-like molecules.